A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.-MedSci.cn

A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.

Tsimberidou, AM; Ajani, JA; Hsu, P; Chen, IJ; Pearce, TE

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务